AYTU BIOPHARMA INC

AYTUNASDAQ

🏆 #4727 by market capUS Equity

$2.15▼ $0.10 (−4.44%)

Market closed · at close

🔔

Track AYTU

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.4%

7d▼ 2.7%

14d▲ 8.6%

30d▼ 5.3%

ytd▼ 17.6%

1y▲ 15.0%

🏦Market Cap

$23M

Small Cap

📈Revenue Growth (YoY)

-13.3%

Declining

📊Gross Margin

64.0%

High

💵FCF Margin

14.0%

Healthy

⚖️P/S Ratio

0.4x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $2.13 – $2.17
52-Week Range: $1.65 – $3.07
Volume: $1.59B
Avg Volume: $2.03B
Shares Outstanding: 10.7M
Next Earnings: Dec 10, 2026

Fundamentals Snapshot

Annual Revenue: $58M
Last Q Revenue: $16M
P/E Ratio: —
P/S Ratio: 0.4x
EPS (TTM): $-1.49
Dividend Yield: —
Dilution (1yr): +22.7%

Why Investors Own AYTU

✓High-growth profile — revenue up -6.5% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 19% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AYTU BIOPHARMA INC

AYTU

Financial Trends

Revenue

$58M▼ −13.3% YoY

Gross Margin

64.0%▼ −7.4% YoY

Operating Income

−$8M▲ +6.2% YoY

Free Cash Flow

$3M▼ −163.0% YoY

Shares Outstanding

12.3M▲ +22.7% YoY

Net Cash

$8M▲ +$1M YoY

StockOtter · stockotter.space

About AYTU BIOPHARMA INC

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

🦦